journal
https://read.qxmd.com/read/38408468/correction-to-lancet-respir-med-2024-12-129-40
#21
(no author information available yet)
No abstract text is available yet for this article.
February 23, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38408467/reframing-sepsis-immunobiology-for-translation-towards-informative-subtyping-and-targeted-immunomodulatory-therapies
#22
REVIEW
Manu Shankar-Hari, Thierry Calandra, Miguel P Soares, Michael Bauer, W Joost Wiersinga, Hallie C Prescott, Julian C Knight, Kenneth J Baillie, Lieuwe D J Bos, Lennie P G Derde, Simon Finfer, Richard S Hotchkiss, John Marshall, Peter J M Openshaw, Christopher W Seymour, Fabienne Venet, Jean-Louis Vincent, Christophe Le Tourneau, Anke H Maitland-van der Zee, Iain B McInnes, Tom van der Poll
Sepsis is a common and deadly condition. Within the current model of sepsis immunobiology, the framing of dysregulated host immune responses into proinflammatory and immunosuppressive responses for the testing of novel treatments has not resulted in successful immunomodulatory therapies. Thus, the recent focus has been to parse observable heterogeneity into subtypes of sepsis to enable personalised immunomodulation. In this Personal View, we highlight that many fundamental immunological concepts such as resistance, disease tolerance, resilience, resolution, and repair are not incorporated into the current sepsis immunobiology model...
February 23, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38408466/us-epa-strengthens-pm-2%C3%A2-5-air-pollution-limits
#23
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
February 23, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38401557/correction-to-lancet-respir-med-2024-published-online-jan-3-https-doi-org-10-1016-s2213-2600-23-00412-5
#24
(no author information available yet)
No abstract text is available yet for this article.
February 21, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38359853/a-tobacco-free-generation-the-end-goal-of-the-endgame
#25
EDITORIAL
The Lancet Respiratory Medicine
No abstract text is available yet for this article.
February 12, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38340746/tuberculosis-conflict-and-displacement
#26
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
February 7, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38310918/hydrocortisone-plus-fludrocortisone-for-community-acquired-pneumonia-related-septic-shock-a-subgroup-analysis-of-the-aprocchss-phase-3-randomised-trial
#27
JOURNAL ARTICLE
Nicholas Heming, Alain Renault, Emmanuelle Kuperminc, Christian Brun-Buisson, Bruno Megarbane, Jean-Pierre Quenot, Shidasp Siami, Alain Cariou, Xavier Forceville, Carole Schwebel, Marc Leone, Jean-Francois Timsit, Benoît Misset, Mohamed Ali Benali, Gwenhael Colin, Bertrand Souweine, Karim Asehnoune, Emmanuelle Mercier, Loïc Chimot, Claire Charpentier, Bruno François, Thierry Boulain, Frank Petitpas, Jean Michel Constantin, Gilles Dhonneur, François Baudin, Alain Combes, Julien Bohé, Jean-François Loriferne, Fabrice Cook, Michel Slama, Olivier Leroy, Gilles Capellier, Auguste Dargent, Tarik Hissem, Rania Bounab, Virginie Maxime, Pierre Moine, Eric Bellissant, Djillali Annane
BACKGROUND: Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock. METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups...
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38310917/transitioning-to-gaseous-and-liquid-fuels-a-right-step-towards-clean-cooking-in-low-income-and-middle-income-countries
#28
JOURNAL ARTICLE
Anindita Dutta, Christopher O Olopade
No abstract text is available yet for this article.
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38310916/corticosteroids-in-septic-shock-secondary-to-community-acquired-pneumonia-clarity-mixed-with-uncertainty
#29
JOURNAL ARTICLE
Balasubramanian Venkatesh, Jeremy Cohen
No abstract text is available yet for this article.
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38310915/health-effects-of-gas-fuels-interpreting-evidence-from-a-comprehensive-meta-analysis
#30
JOURNAL ARTICLE
John Norrie
No abstract text is available yet for this article.
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38310914/estimated-health-effects-from-domestic-use-of-gaseous-fuels-for-cooking-and-heating-in-high-income-middle-income-and-low-income-countries-a-systematic-review-and-meta-analyses
#31
JOURNAL ARTICLE
Elisa Puzzolo, Nigel Fleeman, Federico Lorenzetti, Fernando Rubinstein, Yaojie Li, Ran Xing, Guofeng Shen, Emily Nix, Michelle Maden, Rebecca Bresnahan, Rui Duarte, Lydia Abebe, Jessica Lewis, Kendra N Williams, Heather Adahir-Rohani, Daniel Pope
BACKGROUND: Exposure to household air pollution from polluting domestic fuel (solid fuel and kerosene) represents a substantial global public health burden and there is an urgent need for rapid transition to clean domestic fuels. Gas for cooking and heating might possibly affect child asthma, wheezing, and respiratory health. The aim of this review was to synthesise the evidence on the health effects of gaseous fuels to inform policies for scalable clean household energy. METHODS: In this systematic review and meta-analysis, we summarised the health effects from cooking or heating with gas compared with polluting fuels (eg, wood or charcoal) and clean energy (eg, electricity and solar energy)...
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38309287/first-line-penpulimab-combined-with-paclitaxel-and-carboplatin-for-metastatic-squamous-non-small-cell-lung-cancer-in-china-ak105-302-a-multicentre-randomised-double-blind-placebo-controlled-phase-3-clinical-trial
#32
JOURNAL ARTICLE
Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui, Zhihong Zhang, Hui Luo, Weiyou Liu, Meili Sun, Jingxun Wu, Yongchun Shen, Shucai Zhang, Nong Yang, Mengzhao Wang, Junguo Lu, Kai Li, Weirong Yao, Qian Sun, Hongmei Yue, Lin Wang, Sheng Ye, Bin Li, Xibin Zhuang, Yueyin Pan, Min Zhang, Yongqian Shu, Zhiyong He, Lei Pan, Yang Ling, Shengming Liu, Qi Zhang, Shunchang Jiao, Baohui Han
BACKGROUND: Penpulimab is a novel programmed death (PD)-1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non-small-cell lung cancer. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial enrolled patients with locally advanced or metastatic squamous non-small-cell lung cancer from 74 hospitals in China. Eligible participants were aged 18-75 years, had histologically or cytologically confirmed locally advanced (stage IIIb or IIIc) or metastatic (stage IV) squamous non-small-cell lung cancer, were ineligible to complete surgical resection and concurrent or sequential chemoradiotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, did not have previous systemic chemotherapy for locally advanced or metastatic non-small-cell lung cancer, and had one or more measurable lesions according to RECIST (version 1...
January 31, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38278163/us-senate-committee-investigates-asthma-inhaler-prices
#33
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
January 23, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38272050/individualised-short-course-antibiotic-treatment-versus-usual-long-course-treatment-for-ventilator-associated-pneumonia-regard-vap-a-multicentre-individually-randomised-open-label-non-inferiority-trial
#34
JOURNAL ARTICLE
Yin Mo, Suchart Booraphun, Andrew Yunkai Li, Pornanan Domthong, Gyan Kayastha, Yie Hui Lau, Ploenchan Chetchotisakd, Direk Limmathurotsakul, Paul Anantharajah Tambyah, Ben S Cooper
BACKGROUND: Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish whether a pragmatic, individualised, short-course antibiotic treatment strategy for VAP was non-inferior to usual care. METHODS: We did an individually randomised, open-label, hierarchical non-inferiority-superiority trial in 39 intensive care units in six hospitals in Nepal, Singapore, and Thailand...
January 22, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38272049/optimising-antibiotic-treatment-duration-in-ventilator-associated-pneumonia
#35
JOURNAL ARTICLE
Emma D Johnson, James D Chalmers
No abstract text is available yet for this article.
January 22, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38272048/what-is-next-for-bcg-revaccination-to-prevent-tuberculosis
#36
LETTER
Richard G White, Andrew J Fiore-Gartland, Willem A Hanekom, Johan Vekemans, Alberto L Garcia-Basteiro, Gavin Churchyard, Molebogeng X Rangaka, Mike Frick, Marcel A Behr, Philip C Hill, Vidya Mave
No abstract text is available yet for this article.
January 22, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38262429/antibiotic-prophylaxis-for-patients-with-acute-brain-injury
#37
JOURNAL ARTICLE
Michael Klompas
No abstract text is available yet for this article.
January 19, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38262428/ceftriaxone-to-prevent-early-ventilator-associated-pneumonia-in-patients-with-acute-brain-injury-a-multicentre-randomised-double-blind-placebo-controlled-assessor-masked-superiority-trial
#38
JOURNAL ARTICLE
Claire Dahyot-Fizelier, Sigismond Lasocki, Thomas Kerforne, Pierre-Francois Perrigault, Thomas Geeraerts, Karim Asehnoune, Raphaël Cinotti, Yoann Launey, Vincent Cottenceau, Marc Laffon, Thomas Gaillard, Matthieu Boisson, Camille Aleyrat, Denis Frasca, Olivier Mimoz
BACKGROUND: Patients with acute brain injury are at high risk of ventilator-associated pneumonia (VAP). The benefit of short-term antibiotic prophylaxis remains debated. We aimed to establish the effect of an early, single dose of the antibiotic ceftriaxone on the incidence of early VAP in patients with severe brain injury who required mechanical ventilation. METHODS: PROPHY-VAP was a multicentre, randomised, double-blind, placebo-controlled, assessor-masked, superiority trial conducted in nine intensive care units in eight French university hospitals...
January 19, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38237620/morphine-for-treatment-of-cough-in-idiopathic-pulmonary-fibrosis-pacify-cough-a-prospective-multicentre-randomised-double-blind-placebo-controlled-two-way-crossover-trial
#39
JOURNAL ARTICLE
Zhe Wu, Lisa G Spencer, Winston Banya, John Westoby, Veronica A Tudor, Pilar Rivera-Ortega, Nazia Chaudhuri, Ira Jakupovic, Brijesh Patel, Muhunthan Thillai, Alex West, Marlies Wijsenbeek, Toby M Maher, Jacky A Smith, Philip L Molyneaux
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared with placebo as an antitussive therapy in individuals with idiopathic pulmonary fibrosis. METHODS: The PACIFY COUGH study is a phase 2, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial done in three specialist centres in the UK...
January 15, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38237619/opioids-bring-peace-to-patients-with-ipf-cough
#40
JOURNAL ARTICLE
Dominic L Sykes, Simon P Hart
No abstract text is available yet for this article.
January 15, 2024: Lancet Respiratory Medicine
journal
journal
47869
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.